Surrozen Highlights SZN-043 Data on Safety and Liver Function

An update from Surrozen (SRZN) is now available.

Surrozen, Inc. recently unveiled new data on SZN-043, emphasizing safety, pharmacodynamics, and liver function, through a press release and a detailed corporate presentation. While these materials provide valuable insights, they are not considered official filings under the Securities Exchange Act, nor are they automatically included in any Securities Act filings unless explicitly referenced. This disclosure by Surrozen is part of their ongoing commitment to transparency and should not be interpreted as a legally required revelation.

For a thorough assessment of SRZN stock, go to TipRanks’ Stock Analysis page.